Brought to you by

Pernix issues $25mm in stock to buy Silenor marketer Somaxon Pharmaceuticals
19 Dec 2012
Executive Summary
Pernix Therapeutics Holdings Inc. (brand, generic, and OTC products) is issuing $25mm of its common stock--about 3.4mm shares based on the ten-day average--to acquire publicly traded spec pharmaco Somaxon Pharmaceuticals Inc., which has been evaluating strategic alternatives since December 2011.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com